Published in Life Sci on December 05, 2005
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS One (2009) 1.12
miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol (2014) 0.99
Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 0.97
Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am (2010) 0.94
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int (2009) 0.93
A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer (2011) 0.92
The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis (2015) 0.91
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol (2006) 0.88
Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis (2015) 0.86
Adverse childhood experiences and leukocyte telomere maintenance in depressed and healthy adults. J Affect Disord (2014) 0.83
Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS One (2010) 0.81
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol (2014) 0.81
Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol (2010) 0.79
Prognostic and clinicopathological significance of serum interleukin-6 expression in colorectal cancer: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.75
Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases. Front Pharmacol (2016) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
The serial cultivation of human diploid cell strains. Exp Cell Res (1961) 25.11
Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell (1985) 24.17
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 12.35
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Telomere loss: mitotic clock or genetic time bomb? Mutat Res (1992) 6.50
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol (1998) 4.59
Senescence induced by altered telomere state, not telomere loss. Science (2002) 4.17
Telomerases. Annu Rev Biochem (1992) 3.83
Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A (1995) 3.79
DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res (2002) 3.22
Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet (1998) 3.01
Worldwide trends in mortality from biliary tract malignancies. BMC Cancer (2002) 2.61
Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology (2005) 2.56
Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem (1999) 2.34
Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol (2002) 2.25
Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology (1999) 2.20
Cholangiocarcinoma: current concepts and insights. Hepatology (2003) 1.96
The role of senescence and immortalization in carcinogenesis. Carcinogenesis (2000) 1.67
Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res (2002) 1.64
Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem (1999) 1.53
Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49
Regulation of the human telomerase reverse transcriptase gene. Oncogene (2002) 1.47
Telomeres and senescence: the history, the experiment, the future. Curr Biol (1998) 1.40
Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J Biol Chem (1998) 1.38
Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology (1999) 1.33
Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Mol Cell Biol (2001) 1.32
Role of telomerase in normal and cancer cells. J Clin Oncol (2000) 1.32
Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem (1997) 1.28
Telomeres, telomerase and cancer: an up-date. Virchows Arch (2000) 1.18
Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol (1995) 1.07
Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog (1999) 1.06
Detection of telomerase activity utilizing energy transfer primers: comparison with gel- and ELISA-based detection. Biotechniques (1999) 1.01
Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology (2001) 0.95
Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. Hepatology (2003) 0.93
Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc (2000) 0.89
In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc (1998) 0.85
In situ nucleic acid detection of human telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion. Hepatology (1999) 0.82
Increased telomerase activity in intrahepatic cholangiocellular carcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Cancer Lett (1998) 0.81
Aging clock: the watchmaker's masterpiece. Cell Mol Life Sci (2000) 0.80
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Surgical treatment of permanent diaphragm paralysis after interscalene nerve block for shoulder surgery. Anesthesiology (2013) 4.25
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology (2010) 2.23
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem (2007) 1.90
Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.87
A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine (Phila Pa 1976) (2004) 1.86
Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol (2002) 1.83
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res (2006) 1.80
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol (2005) 1.69
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol (2007) 1.56
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular Signaling in Human Hepatocellular Cancer. Genes Cancer (2013) 1.47
Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int (2006) 1.45
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol (2008) 1.43
MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology (2008) 1.43
The role of microRNAs in human liver cancers. Semin Oncol (2011) 1.34
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
Identifying opportunities for improved colorectal cancer screening in primary care. Prev Med (2004) 1.26
Long noncoding RNA in liver diseases. Hepatology (2014) 1.23
gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res (2005) 1.23
Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol (2011) 1.20
Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res (2010) 1.17
The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med (2014) 1.13
Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine (Phila Pa 1976) (2005) 1.12
Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res (2004) 1.09
The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study. Spine (Phila Pa 1976) (2008) 1.09
Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci (2014) 1.09
Use of bone morphogenetic proteins for musculoskeletal applications. An overview. J Bone Joint Surg Am (2004) 1.09
The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J (2007) 1.08
Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol (2006) 1.07
Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry (2005) 1.07
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (2011) 1.07
H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res (2009) 1.06
Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. Am J Physiol Gastrointest Liver Physiol (2003) 1.05
A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J (2003) 1.05
Inhibition of cholangiocarcinoma growth by tannic acid. Hepatology (2003) 1.04
Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep (2006) 1.03
The role of melatonin in anaesthesia and critical care. Indian J Anaesth (2013) 1.02
A 2-year follow-up pilot study evaluating the safety and efficacy of op-1 putty (rhbmp-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J (2005) 0.99
Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets (2012) 0.96
Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clin Gastroenterol Hepatol (2004) 0.96
Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol (2009) 0.94
Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. Hepatology (2002) 0.94
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol (2011) 0.94
Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am (2010) 0.94
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One (2013) 0.93
Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. Am J Physiol Gastrointest Liver Physiol (2011) 0.93
Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. Hepatology (2003) 0.93
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int (2009) 0.93
microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem (2013) 0.91
Reversible non-ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single-centre experience. Liver Int (2014) 0.90
Hepatic miR-29ab1 expression modulates chronic hepatic injury. J Cell Mol Med (2012) 0.89
Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer (2009) 0.89
Recent advances in the morphological and functional heterogeneity of the biliary epithelium. Exp Biol Med (Maywood) (2013) 0.89
The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol (2006) 0.89
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol (2006) 0.88
Modulation of the biliary expression of arylalkylamine N-acetyltransferase alters the autocrine proliferative responses of cholangiocytes in rats. Hepatology (2013) 0.88
Endoscopic ultrasound versus CT scan for detection of the metastases to the liver: results of a prospective comparative study. J Clin Gastroenterol (2009) 0.88
Activation of alpha(1) -adrenergic receptors stimulate the growth of small mouse cholangiocytes via calcium-dependent activation of nuclear factor of activated T cells 2 and specificity protein 1. Hepatology (2011) 0.88
Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity. Dig Liver Dis (2011) 0.87
Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer. Brief Funct Genomics (2015) 0.87
Increased susceptibility of cholangiocytes to tumor necrosis factor-alpha cytotoxicity after bile duct ligation. Am J Physiol Cell Physiol (2003) 0.87
Transforming growth factor-beta inhibition of proteasomal activity: a potential mechanism of growth arrest. Am J Physiol Cell Physiol (2003) 0.87
Isolation of extracellular nanovesicle microRNA from liver cancer cells in culture. Methods Mol Biol (2013) 0.87
Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis. J Biol Chem (2013) 0.87
IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway. Am J Physiol Cell Physiol (2005) 0.86
Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms. Lab Invest (2011) 0.86
GABA induces the differentiation of small into large cholangiocytes by activation of Ca(2+) /CaMK I-dependent adenylyl cyclase 8. Hepatology (2013) 0.84
Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. Gastroenterology (2004) 0.84
Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells. Am J Physiol Cell Physiol (2007) 0.83
Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Transl Gastrointest Cancer (2012) 0.83
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology (2010) 0.82
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. Am J Physiol Cell Physiol (2011) 0.81
Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS One (2010) 0.81
Double-stranded RNA activates a p38 MAPK-dependent cell survival program in biliary epithelia. Am J Physiol Gastrointest Liver Physiol (2003) 0.81
Fine-needle aspiration of metanephric adenoma of the kidney with clinical, radiographic and histopathologic correlation: a review. Diagn Cytopathol (2013) 0.81
An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. J Assoc Physicians India (2011) 0.80
Effect of thermal stability on protein adsorption to silica using homologous aldo-keto reductases. Protein Sci (2012) 0.80
Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expr (2014) 0.80
Tannic acid inhibits cholangiocyte proliferation after bile duct ligation via a cyclic adenosine 5',3'-monophosphate-dependent pathway. Am J Pathol (2005) 0.80
Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.80
Screening for colorectal cancer in elderly persons: who should we screen and when can we stop? J Aging Health (2007) 0.80
Autoimmune cholangiopathy and high-output heart failure in a patient with graves disease. Gastroenterol Hepatol (N Y) (2011) 0.79
Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes. J Pharmacol Exp Ther (2006) 0.79
Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 0.79